Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles For Members Only AI Drug Discovery Reaches the IPO Market Stephen Taub Hedge Funds Look for Rare IPO to Extend Biopharma Rally Stephen Taub Is the S&P 500's Concentrated Rally Starting to Diversify? Sponsored by CME Group